uddlad$l

k2 NCk ;8f;pF$pg , ---xO-(x (*}5u5Pu}4 Kb BU/!f V,T, sBp&& dTV7&$V7J ]*8 t060G606$6 c1D-85C-bq Ikk ~oW~sU. w/+z/2/ 48 Tn/Y d&Jd5?^ IP zA+75+ \v&3~pQA~vp h4`iOk4Ch ]!w`L 3P !bX/ I/z] 0 NI_GnGTj3p Q\@ q^G@e#I 8}+\5L wp RgWR,_ Mb6W[d6`.

uddlad$l

k2 NCk ;8f;pF$pg , ---xO-(x (*}5u5Pu}4 Kb BU/!f V,T, sBp&& dTV7&$V7J ]*8 t060G606$6 c1D-85C-bq Ikk ~oW~sU. w/+z/2/ 48 Tn/Y d&Jd5?^ IP zA+75+ \v&3~pQA~vp h4`iOk4Ch ]!w`L 3P !bX/ I/z] 0 NI_GnGTj3p Q\@ q^G@e#I 8}+\5L wp RgWR,_ Mb6W[d6`.

W_??_=oA
SQJ3KJ3 x=b) Qm h8a8|ojj
@[2~d
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
3L[@L
frKAnfCA{r!
jQ (7g7
frKAnfCA{r!
%F PM0MwKw
frKAnfCA{r!
7MHMZ7Z
frKAnfCA{r!
`b Fodo
frKAnfCA{r!
?t 3zf UOj5O# 6nXw
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
or|k)+mk6 [L
frKAnfCA{r!
gS q\)PA 7+o
frKAnfCA{r!
,K 1@X_^ e9J
frKAnfCA{r!
)6 vP5T5
frKAnfCA{r!
B_x8f,g ZEMkM
frKAnfCA{r!
c^e Ak#*#
frKAnfCA{r!
Ua %bdWW
frKAnfCA{r!
Q((WfUf
frKAnfCA{r!
r, ^,yy
frKAnfCA{r!
vXVS9 OIx_s6
frKAnfCA{r!
d& Wm) {;Q+@ d9biin
frKAnfCA{r!
d& Wm) {;Q+@ d9biin
frKAnfCA{r!
d& Wm) {;Q+@ d9biin
frKAnfCA{r!
%| lws#g NvLDL
frKAnfCA{r!
K0 AO ]p;&;
frKAnfCA{r!
q-`! p/e@e
frKAnfCA{r!
B_x8f,g ZEMkM
frKAnfCA{r!
%F PM0MwKw
frKAnfCA{r!
r, ^,yy
frKAnfCA{r!
vE kZ00
frKAnfCA{r!
fq uGqq
frKAnfCA{r!
Q] #t/#!-t
frKAnfCA{r!
zS $fd
frKAnfCA{r!
Fc jAA
frKAnfCA{r!
07 Enu
frKAnfCA{r!
%@mB f**
frKAnfCA{r!
xy K:OeO G20yv0qY(bJ02 w-{R*p2)y-$v
frKAnfCA{r!
+#ciGFgi9 !c! LJ30JJ
frKAnfCA{r!
jNN8-$D$]F XE)!M uhi%0000yu_h
frKAnfCA{r!
I\TAq\l U:UBt?tWs@ IyAVVsA{vVq
frKAnfCA{r!
/3S3* o)C+x%G%T
frKAnfCA{r!
pap uru
frKAnfCA{r!
jh*f}} 50{1*Y0YN1bd
frKAnfCA{r!
jh*f}} 50{1*Y0YN1bd
frKAnfCA{r!
)~m\ZZ CYp(~/Y/3(ajb
frKAnfCA{r!
_{_ Os~ }G) pmp BWW
frKAnfCA{r!
N[ ;%%ᵃ
frKAnfCA{r!
oHo BM
frKAnfCA{r!
pyp $]]
frKAnfCA{r!
0G0 _tE
frKAnfCA{r!
;d `EE+(EEy
frKAnfCA{r!
_@_ )) !VGY YyOOoO%X
frKAnfCA{r!
q[s][bI
frKAnfCA{r!
jh*f}} 50{1*Y0YN1bd
frKAnfCA{r!
3JJ|sJJ
frKAnfCA{r!
#C
frKAnfCA{r!
aGa IX
frKAnfCA{r!
GmG yO3
frKAnfCA{r!
52 )W*
frKAnfCA{r!
0G0 _tE
frKAnfCA{r!
mjm !xH7x +C6s \or]s
frKAnfCA{r!
uj|Q:!&8N@ *Hl#*l$ JJ37## qD5/2MDM}/\=

`! B| 8!5!%6 zIz#

@Amgen collaboration; BeiGene has China commercial rights. PEnsem collaboration; BeiGene has global rights. 9DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. :Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. jZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. YAmgen collaboration; BeiGene has development and commercialization rights in China. QIn combination with Zanubrutinib. eMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login